Reconstruction of Saccular and Dissected Intracranial Aneurysms Using Solitaire™ AB Stents

Kai-Jun Zhao1*, Yong-Wei Zhang2*, Yi Xu1, Bo Hong1, Qing-Hai Huang1, Wen-Yuan Zhao1, Peng-Fei Yang1, Jian-Min Liu1*

1 Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, China, 2 Department of Neurology & Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, China

Abstract

Introduction: We aimed to evaluate the feasibility, safety, efficacy, and predictors for outcome of reconstructive treatment with Solitaire™ AB stent(s) based on 54 cases of saccular aneurysms and 14 of acute symptomatic dissecting aneurysms.

Methods: Fifty-eight consecutive patients (M/F = 28/30; median age, 53 years) harbouring 68 aneurysms (ruptured/unruptured = 12/56) underwent treatment with Solitaire™ AB stent(s) implantation between April 2010 and August 2011 in our institution. The data were retrospectively reviewed and analysed.

Results: The technical success rate of Solitaire™ AB stenting was 100%. The rates of the overall and the treatment-related adverse events were 9% (6/68) and 6% (4/68), respectively, and the recurrent rate was 1% (1/68). All of the adverse events (n = 6) occurred in tiny (n = 1, ≤3 mm) or small (n = 5, >3 to ≤10 mm) aneurysms. The majority (75%, 3/4) of thromboembolic events (thrombus, n = 2; infarction, n = 2) occurred in ruptured lesions, and 2 intra procedural aneurysm ruptures occurred in the course of coiling when the stent(s) was/were applied within 6 months. Subarachnoid haemorrhages (SAH, p < 0.05) and immediate occlusion grades (p < 0.05) were predictors for overall adverse events by univariate analysis. Compared with the immediate post-treatment angiographic results, the follow-up angiographic imaging (mean, 13 months; range, 6–25 months) revealed that stent(s) implantation enhanced the rate of class I occlusion from 34% (23/68) to 93% (63/68). SAH was the only predictor for unfavourable outcomes (the modified Rankin Scale score [mRS], 2–6) during the mean 19-month (range, 12–27 months) of clinical follow-ups (p < 0.05).

Conclusions: Although the complete obliteration of tiny and small aneurysms without complications remains a challenge, stent(s) implantation could lead to further occlusion of incompletely coiled aneurysms. SAH and the occlusion grade were the primary predictors for adverse events. SAH was the only predictor for unfavourable outcomes by univariate analysis.

Introduction

Endovascular coiling has emerged as the first-line treatment option for wide-necked intracranial aneurysms [1,2]. For certain ruptured or unruptured wide-necked aneurysms, the appropriate adjunctive tools are crucial [3]. Compared with balloon-assisted coiling, stent-assisted coiling can provide a “scaffolding” for denser packing, reducing the risks of recurrence and rebleeding. The use of stenting alone has also been well applied for tiny [4] and fusiform aneurysms [5]. The multiple stents overlapping technique [6,7] is also an alternative for the reconstruction of dissecting aneurysms in acute cases, such as SAH, acute posterior circulation stroke or neck pain.

Recently, 58 suitable patients harbouring 68 aneurysms underwent individualised treatment with a new stent (“Solitaire™ AB”) and the forgoing techniques in our institution. Although several small studies have provided preliminary results regarding the use of Solitaire™ stents for saccular aneurysms [8,9], the predictors for unfavourable outcomes (mRS, 2–6) [10] related to Solitaire™ have not been fully elucidated. Moreover, little is known of the Solitaire™ AB stent results for the treatment of acute symptomatic dissecting aneurysms. Additionally, stenting-only with Solitaire™ stent(s) for the treatment of saccular or dissecting lesions has not been reported. Although the aneurysms in this study were of different aetiologies, they were commonly analysed since they were all suitable for endovascular reconstruction with Solitaire™ AB stent(s).

Materials and Methods

This retrospective study was approved by our institution’s ethics committee.
Patients
A retrospective review was conducted on the inpatient and outpatient angiographic and clinical charts to identify cases in our institution treated with Solitaire™ AB (Covidien/ev3) stent implantation between April 2010 and August 2011. The exclusion criteria included: (1) cases treated with different types of stents (n = 3); (2) cases lost to follow-up (n = 4). A total of 58 consecutive patients (M/F = 28/30; median age, 53 years; range, 17–77 years) harbouring 68 intracranial aneurysms (Hunt-Hess grade: 0–II in 57, IV in 1) were identified and enrolled in this study.

Aneurysms
The dissecting aneurysms were diagnosed when fusiform or irregular dilatations of the intradural artery trunk were revealed by vascular imaging. A total of 52 saccular aneurysms (ruptured/unruptured = 9/43) and 3 unruptured symptomatic internal carotid artery dissection aneurysms (ICADAs) were located in the anterior circulation. The remaining 2 unruptured saccular aneurysms and 11 symptomatic intradural vertebral artery dissection aneurysms (VADAs, ruptured/unruptured = 3/8) were located in the posterior circulation, including 3 posterior inferior cerebellar artery (PICA)-involving lesions (ruptured/unruptured = 1/2). According to the morphology as seen by angiographic imaging, this series included 6 fusiform dissecting and 8 lateral protrusion-shaped dissecting aneurysms. Of the 68 lesions, 18 were designated as tiny (≤3 mm), 47 as small (>3 to ≤10 mm), and 3 as large (>10 to ≤25 mm) based on their maximum diameters. All the saccular and lateral protrusion-shaped dissecting aneurysms (n = 8) were wide-necked (neck>4 mm or dome/neck ratio<2), and the 6 fusiform aneurysms had no defined neck.

Procedures
Two hours prior to the procedure, the patients with acutely ruptured aneurysms were preloaded with 300 mg clopidogrel and 300 mg aspirin. All the patients with unruptured aneurysms were preloaded daily with clopidogrel (75 mg) and aspirin (100 mg) for 3 days prior to the procedure. All the patients received systemic intravenous heparin after placement of the femoral sheath for an activated clotting time between 250–300 seconds. All the patients were treated under general anaesthesia by experienced interventional neurosurgeons. The stent placement was defined as a successful implantation if the single stent, or the multiple telescopically overlapped stents, extended at least 5 mm past each side of the aneurysm neck (saccular and lateral protrusion-shaped dissection aneurysms) or past the border of the dissection lesions (fusiform-shaped) of the target vessel. Post-procedure, the patients were kept on a 6-week dural antiplatelet regimen of 75 mg Plavix and 100 mg aspirin daily, followed by 100 mg aspirin indefinitely.

Follow-ups
Angiographic control follow-ups were performed with conventional angiography at 6 months, 12 months, and annually thereafter. For fusiform dissecting aneurysms, the immediate and follow-up occlusion grades were defined as complete obliteration (class I), near-complete obliteration (class II), and partial obliteration (class III) [11]. For saccular and lateral protrusion-shaped dissecting aneurysms, the occlusion grade was defined as complete occlusion (class I), residual neck (class II), and residual aneurysm (class III) based on the Raymond classification [12]. For the cases treated by stenting alone, the residual contrast time within the aneurysm was increased moderately after the stent(s) implantation, and this was also regarded as a class III occlusion. The angiographic results were interpreted independently by 3 authors (Jian-Min Liu, Qing-Hai Huang and Wen-Yuan Zhao, each with

Table 1. The Immediate and Follow-up Angiographic Results of 68 Lesions Reconstructed with Different Methods.

| Variables               | Lesions     | Immediate Results | Follow-up Results | Total |
|-------------------------|-------------|-------------------|-------------------|-------|
| Single stent with coils |             |                   |                   |       |
| Yes ICADAs              | Class II    | Cured             | 2                 |       |
| Yes Saccular            | Class I     | Cured             | 23                |       |
| Yes Saccular            | Class II    | Cured             | 11                |       |
| Yes Saccular            | Class III   | Cured             | 13                |       |
| Yes Saccular            | Class III   | Improved          | 1                 |       |
| Total                   |             |                   |                   | 50    |
| Stenting-only           |             |                   |                   |       |
| Single stent Saccular   | Class III   | Unchanged         | 3                 |       |
| Multiple stents VADAs   | Class III   | Cured             | 3                 |       |
| Total                   |             |                   |                   | 6     |
| Multiple stents with coils |         |                   |                   |       |
| Yes VADAs               | Class III   | Cured             | 7                 |       |
| Yes VADA                | Class III   | Recurrence        | 1                 |       |
| Yes ICADA               | Class III   | Cured             | 1                 |       |
| Yes Saccular            | Class III   | Cured             | 2                 |       |
| Yes Saccular            | Class II    | Cured             | 1                 |       |
| Total                   |             |                   |                   | 12    |

ICADA(s), internal carotid artery dissection aneurysm(s); VADA(s), vertebral artery dissection aneurysm(s).

doi:10.1371/journal.pone.0057253.t001
Table 2. Impact of Patient Demographics (n = 58) and Aneurysm Characteristics (n = 68) on Adverse Events.

| Variables                          | Thromboembolism (n = 4) | Rupture (n = 2) | Overall Adverse Events (n = 6) |
|------------------------------------|-------------------------|-----------------|-------------------------------|
|                                    | Yes | No | p   | Yes | No | p   | Yes | No | p   |
| Patient Sex, no. (%)               |     |    |     |     |    |     |     |    |     |
| Male                               | 28  | 1 (4) | 27 (96) | 1 (4) | 27 (96) | 2 (7) | 26 (93) | 0.66 | 1.00 | 0.73 |
| Female                             | 30  | 3 (10) | 27 (90) | 1 (3) | 29 (97) | 4 (13) | 26 (87) |     |      |     |
| SAH, no. (%)                       |     |    |     |     |    |     |     |    |     |
| Ruptured                           | 12  | 3 (25) | 9 (75) | 1 (8) | 11 (92) | 4 (33) | 8 (67) | 0.02 | 0.32 | 0.006 |
| Unruptured                         | 56  | 1 (2) | 55 (98) | 1 (2) | 55 (98) | 2 (4) | 54 (96) |     |      |     |
| Aneurysm location, no. (%)         |     |    |     |     |    |     |     |    |     |
| Anterior circulation               | 55  | 4 (7) | 51 (93) | 2 (4) | 53 (96) | 9 (16) | 46 (84) | 1.00 | 1.00 | 0.27 |
| Posterior circulation              | 13  | 0 (0) | 13 (100) | 0 (0) | 13 (100) | 0 (0) | 13 (100) |     |      |     |
| Aneurysm shape, no. (%)            |     |    |     |     |    |     |     |    |     |
| Saccular aneurysm                  | 54  | 4 (7) | 50 (93) | 2 (4) | 52 (96) | 9 (17) | 45 (83) | 0.57 | 1.00 | 0.23 |
| Dissection aneurysm                | 14  | 0 (0) | 14 (100) | 0 (0) | 14 (100) | 0 (0) | 14 (100) |     |      |     |
| Aneurysm size, no. (%)             |     |    |     |     |    |     |     |    |     |
| Tiny                               | 18  | 1 (6) | 17 (94) | 0 (0) | 18 (100) | 2 (11) | 16 (89) | 0.90 | 0.63 | 0.73 |
| Small                              | 47  | 3 (6) | 44 (94) | 2 (4) | 45 (96) | 7 (15) | 40 (85) |     |      |     |
| Large                              | 3   | 0 (0) | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 3 (100) |     |      |     |
| Stent Strategy                     |     |    |     |     |    |     |     |    |     |
| Single stent with or without coiling| 53  | 4 (8) | 49 (92) | 2 (4) | 51 (96) | 6 (11) | 47 (89) | 0.57 | 1.00 | 0.39 |
| Multiple stents with or without coiling| 15  | 0 (0) | 15 (100) | 0 (0) | 15 (100) | 0 (0) | 15 (100) |     |      |     |
| Stent Deployment Technique         |     |    |     |     |    |     |     |    |     |
| Stenting before coiling (mesh technique) | 5   | 0 (0) | 5 (100) | 0 (0) | 5 (100) | 0.66 | 0.82 | 0.006 |     |      |     |
| Stenting after coiling (jailing or semi-jailing) | 57  | 4 (7) | 53 (93) | 2 (4) | 55 (96) | 6 (11) | 51 (89) |     |      |     |
| Stenting-only                      | 6   | 0 (0) | 6 (100) | 0 (0) | 6 (100) | 0 (0) | 6 (100) |     |      |     |
| Coils                              |     |    |     |     |    |     |     |    |     |
| Bare coils                         | 22  | 0 (0) | 22 (100) | 1 (5) | 21 (95) | 1 (5) | 21 (95) | 0.20 | 0.83 | 0.37 |
| Modified (Hydrocoil/soft) coils    | 37  | 4 (11) | 33 (89) | 1 (3) | 36 (97) | 5 (14) | 32 (86) |     |      |     |
| None                               | 6   | 0 (0) | 6 (100) | 0 (0) | 6 (100) | 0 (0) | 6 (100) |     |      |     |
| Occlusion Grade, no. (%)           |     |    |     |     |    |     |     |    |     |
| Class I                            | 23  | 3 (13) | 20 (87) | 2 (9) | 21 (91) | 5 (22) | 18 (78) | 0.13 | 0.13 | 0.03 |
| Class II                           | 14  | 1 (7) | 13 (93) | 0 (0) | 14 (100) | 2 (14) | 12 (86) |     |      |     |
| Class III                          | 31  | 0 (0) | 31 (100) | 0 (0) | 31 (100) | 0 (0) | 31 (100) |     |      |     |

All p values are from Pearson’s x² test or Fisher’s Exact Test (2-sided).

doi:10.1371/journal.pone.0057253.t002

8–12 years of neurointerventional experience) using the Raymond classification. When there was no filling of contrast medium, a substantial shrink of contrast flow, no change of contrast flow, or an increase in contrast flow compared to the control angiogram performed immediately after treatment, the respective diagnoses of angiographic cure, improvement, stability, or recurrence were made. The mRS score acquired via neurologic examination or a telephone interview [13] at the most recent clinical follow-up was considered to be the final outcome and was categorized into two groups: favourable (mRS, 0–1) and unfavourable outcomes (mRS, 2–6) [10]. 10 of the 58 patients had 2 unruptured aneurysms which were independently treated, resulting in a total of 68 treated lesions with clinical follow-up results. All the follow-up results were summarised and analysed in July 2012.

Statistical Analysis

Statistical analysis was performed using the SPSS software package (SPSS 17.0) to evaluate whether the univariate variables, including patient demographics and angiographic features of the aneurysms, had an impact on adverse events or unfavourable outcomes. The categorical and dichotomous variables were examined using Pearson’s x² test or Fisher’s exact test, as appropriate. A p value <0.05 was considered statistically significant.

Results

Treatment and Angiographic Results

The baseline characteristics of the 68 lesions are shown in Tables 1 and 2. The angiographic follow-ups (n = 68) were available for a mean of 13 months (range, 6–25 months). All the embedded stents were successfully performed, and the technical
success rate of the stent placement was 100%. In the early stages (within 6 months) of the Solitaire™ AB stent application, 2 acute in-stent thrombi, 2 intraprocedural aneurysm ruptures, and 2 postprocedural cerebral infarctions were encountered. The rates of the overall and treatment-related adverse events were 9% (6/68) and 6% (4/68), respectively.

Nearly 14% (2/14) of the dissecting aneurysms (2 lateral protrusion-shaped ICADAs) were treated by single stent and coils, and 86% of the dissecting aneurysms (ICADAs, n = 1; VADAs, n = 11) were treated by multiple overlapping stents with (n = 9) or without (n = 3) coils. Although a high rate of class III occlusions (86%, 12/14) was observed in the 14 treated dissecting aneurysms after reconstruction treatment, follow-up angiographic imaging revealed that only 1 (7%) recurred (Fig. 1A–1C), and the remaining 13 (93%) were cured (Table 1). The recurring aneurysm was ultimately resolved by the implantation of an additional Solitaire™ stent.

Eighteen of the 54 (33%) saccular aneurysms were unruptured and tiny; 3 were reconstructed by single stent implantation (Fig. 2A–2C) and 15 by single stent with coils (Fig. 2D–2F). Of the remaining 36 saccular aneurysms, 33 were treated with a single stent with coils and 3 with 2 overlapping stents and coils. Of these 3, 1 required the

Figure 1. Multiple stents with or without coiling for reconstruction of 3 dissecting aneurysms. (A–C) An involving PICA of VADA (A) recurred (C) 6 months after reconstruction with 3 stents and coils with the immediate partial occlusion (B). (D–F) A cured VADA (D vs F) underwent the treatment of 3 Solitaire stents and coils prior to 3 months with the immediate partial occlusion (E). (G–I) Three Solitaire stent implantations cured a VADA (G vs I) with the straightening curvature of the parent artery (H, I).

doi:10.1371/journal.pone.0057253.g001
implantation of a second Solitaire stent due to acute thrombus formation (Case 1) and the remaining 2 due to coil loop herniation. Upon angiographic imaging during the mean 12-month follow-up period, 3 tiny aneurysms treated with a single stent remained unchanged. Of the remaining 51 saccular lesions, 50 were cured, and 1 improved on the follow-up angiographic imaging.

Predictors for Adverse Events and Unfavourable Outcomes

The predictors for outcomes and the management of 6 adverse events are summarised in Tables 3 and 4. All 6 adverse events were encountered during the single stent-assisted coiling for the treatment of tiny (n = 1) or small (n = 5) saccular aneurysms. These adverse events included thromboembolic events (67%, 4/6), whose predictor was SAH (p < 0.05, Table 2), and aneurysm ruptures (33%, 2/6, Fig. 3). Univariate analysis suggested that the ruptures might be incidental because their risks could not be identified (p > 0.05, Table 2). In contrast, the predictors for overall adverse events by univariate analysis (Table 2) primarily involved SAH (p < 0.05) and the occlusion degree (p < 0.05). The clinical follow-ups of all the patients were available (mean, 19 months; range, 12–27 months), and no rebleeding or new neurological events occurred. SAH (p < 0.05) was the only predictor for unfavourable outcomes (mRS, 2–6) by univariate analysis (Table 3).

Figure 2. Reconstruction treatment of 2 tiny aneurysms. (A–C) An unruptured tiny aneurysm (A) was reconstructed with a single Solitaire AB stent. The immediate (B) and 12-month (C) angiographic imagings revealed no change with less effective vessel angle modifications. (D–F) An unruptured tiny aneurysm (D) was reconstructed by a single Solitaire stent with coils, achieving immediate residual aneurysm (E). The 12-month (F) angiographic imaging confirmed total occlusion.

doi:10.1371/journal.pone.0057253.g002

Discussion

The striking advances in intracranial stent characteristics [14] and treatment strategies [4,6,7] have greatly strengthened the ability to treat complex intracranial aneurysms. Several intracranial stents, such as Neuroform [15] and Enterprise [16], have been well applied in the treatment of intracranial aneurysms. Recently, the Solitaire™ AB (Covidien/ev3) stent was introduced to treat intracranial aneurysms [8,9]. The Solitaire™ stent has several advantages compared to its competitors. Firstly, the fully retrievable and detachable characteristics make it very easy to accurately deploy the stent. Secondly, the split-shaped design is favourable for the overlapping of the stent within the relatively smaller-sized vessel, resulting in lower stent porosity. In this study, the individualised treatment strategies, including 1–3 Solitaire™ stent(s) with or without coiling, were employed for the treatment of 68 intracranial dissection and saccular aneurysms. To date, this is the largest Solitaire™ AB stent-related sample study involving reconstructive techniques.

The technical success rate of the stent placement was 100%. The rates of the overall and treatment-related adverse events were 9% (6/68) and 1% (1/68), respectively, and the recurrent rate was 1% (1/68). At follow-ups, 94% (64/68) of the lesions and 95% (55/58) of the patients had favourable angiographic and clinical results (Tables 1 and 3), respectively. Progressive thrombosis, in-stent stenosis or occlusion and rebleeding were not encountered.
These results indicated the feasibility, safety, and efficacy of individualised treatments with the Solitaire stent.

The majority (86%, 12/14) of the dissecting aneurysms were reconstructed using multiple stents with (n = 9) or without (n = 3) coils for the treatment of particular anatomical characteristics, such as lesions with wide-necked lateral protrusion-shaped configurations, fusiform aneurysms without defined necks, PICA-involving lesions, and lesions originating from the artery which has predominant blood supply to the basilar artery. Furthermore, the ruptured dissection aneurysms were all treated with multiple stents and coils due to concerns of rebleeding. In contrast, all the treated small saccular aneurysms, including the tiny ones, were treated due to one of the following reasons: (1) ruptured lesions; (2) symptomatic lesions; (3) anxiety of lesion ruptures by patients with unruptured small or tiny aneurysms (Table 4, Case 2). Despite the development of class III occlusions in 86% of the patients (12/14) receiving 1–3 stent(s) with or without coils, the follow-up angiographic results revealed that 13 were cured and only 1 recurred (Table 1). This may be attributed to several stent-related advantages: (1) “scaffolding” for denser packing [17], primarily involving stenting prior to coiling (mesh technique) and stenting after coiling (jailing or semi-jailing [18]) (Table 2); (2) reconstruction of the diseased parent artery by “endovascular bypass”; (3) the flow diversion or stent-associated flow remodelling [19], resulting in further occlusion of incompletely coiled aneurysms (Fig. 1E–1F); (4) the effective vascular angle modification (Fig. 1G–1I); (5) reattachment of the dissected arterial tissue flap and closing off of the false lumen. One dissecting aneurysm involved the origin of PICA. This aneurysm recurred after treatment with 3 overlapping stents and coils with immediate partial obliteration. An additional Solitaire stent implantation ultimately cured this recurrent lesion, confirming that the relatively lower stent porosity was crucial for preventing the recurrence. This corresponded with an experimental study where hemodynamic modifications were proportional to the number of overlapping stents [20]. In the future, newly designed stents with low porosity, such as the SILK flow diverter [21], may help to overcome the limitations of a high-porosity stent and improve the treatment of saccular and fusiform aneurysms [21,22,23]. Another alternative explanation for the recurrence was that the curvature of the parent vessels bearing the aneurysms were not effectively modified (Fig. 1A–1B). Such modifications are crucial for angiographic outcomes [24,25], as was demonstrated in Fig. 1G–1I.

The majority (94%, 51/54) of the saccular aneurysms were treated with a single stent with (n = 48) or without (n = 3) coils. However, 3 cases were treated with 2 overlapping stents, one of which was treated with a second Solitaire stent implantation for acute thrombus formation (Case 1, Table 4), and the remaining 2 were treated due to coil loop herniation. These 3 cases were all treated with eventual favourable outcomes. Angiographic imaging at the mean 12-month follow-ups revealed that the 3 sole stenting tiny aneurysms remained unchanged. The delayed occlusion time may have been related to less effective angle corrections of the parent vessels (Fig. 2A–2C). Although the class III occlusion rate

Figure 3. Management of intraprocedural aneurysm rupture (A–B) A ruptured MCA-bifurcation aneurysm. (C) Leakage of contrast medium (arrow) and spasmodism of intracerebral arteries. (D) Morphologic presentation of stent and coils. (E) High density haemorrhage area. (F) The 6-month follow-up angiogram showing the total occlusion of the lesion. doi:10.1371/journal.pone.0057253.g003
### Table 3. Effect of Patient Demographics (n = 58) and Aneurysm Angiographic Characteristics (n = 68) on Clinical Outcomes after Endovascular Treatment.

| Variables                       | Favourable Outcomes | Unfavourable Outcomes | Total | $P$ Value |
|---------------------------------|---------------------|-----------------------|-------|-----------|
| **Patient Sex, no. (%)**        |                     |                       |       | 1.00      |
| Male                            | 27 (96)             | 1 (4)                 | 28    |           |
| Female                          | 28 (93)             | 2 (7)                 | 30    |           |
| **SAH, no. (%)**                |                     |                       |       | 0.004     |
| Ruptured                        | 9 (75)              | 3 (25)                | 12    |           |
| Unruptured                      | 56 (100)            | 0 (0)                 | 56    |           |
| **Aneurysm Location, no. (%)**  |                     |                       |       | 1.00      |
| Anterior circulation            | 52 (95)             | 3 (5)                 | 55    |           |
| Posterior circulation           | 13 (100)            | 0 (0)                 | 13    |           |
| **Aneurysm shape, no. (%)**     |                     |                       |       | 1.00      |
| Saccular aneurysm               | 51 (94)             | 3 (6)                 | 54    |           |
| Dissecting aneurysm             | 14 (100)            | 0 (0)                 | 14    |           |
| **Aneurysm Size, no. (%)**      |                     |                       |       | 0.49      |
| Tiny                            | 18 (100)            | 0 (0)                 | 18    |           |
| Small                           | 44 (94)             | 3 (6)                 | 47    |           |
| Large                           | 3 (100)             | 0 (0)                 | 3     |           |
| **Stent Quantity**              |                     |                       |       | 1.00      |
| Single stent with or without coiling | 50 (94) | 3 (6) | 53 | |
| Multiple stents with or without coiling | 15 (100) | 0 (0) | 15 | |
| **Stent Deployment Technique**  |                     |                       |       | 0.74      |
| Stent before coil               | 5 (100)             | 0 (0)                 | 5     |           |
| Stent after coil                | 54 (95)             | 3 (5)                 | 57    |           |
| Stenting-only                   | 6 (100)             | 0 (0)                 | 6     |           |
| **Coils**                       |                     |                       |       | 0.33      |
| Bare coils                      | 22 (100)            | 0 (0)                 | 22    |           |
| Modified (Hydrocoil/soft) coils | 37 (93)             | 3 (7)                 | 40    |           |
| None                            | 6 (100)             | 0 (0)                 | 6     |           |
| **Occlusion Degree, no. (%)**   |                     |                       |       | 0.26      |
| Class I                         | 21 (91)             | 2 (9)                 | 23    |           |
| Class II (including stenting)   | 13 (93)             | 1 (7)                 | 14    |           |

Favourable outcomes (mRS, 0–1); Unfavourable outcomes (mRS, 2–6); All $P$ value are from Pearson’s $x^2$ test or Fisher’s Exact Test (2-sided).

doi:10.1371/journal.pone.0057253.t003

### Table 4. Six Patients and the Management of Adverse Events.

| No | Age /sex | Presentation | H-H | Locations | Saccular /wide-neck | Size | Stent Type | Adverse Events | Measures | Occlusion Grade | Follow-up mRS |
|----|----------|--------------|-----|-----------|---------------------|------|------------|----------------|----------|----------------|---------------|
| 1  | 65/F     | SAH          | II  | MCA-bifur | Yes/Yes             | Small| ST+ST      | Thrombus       | Tirofiban+Stenting | Class I       | 2             |
| 2  | 53/F     | Incidental   | 0   | PComA     | Yes/Yes             | Tiny | ST         | Thrombus       | Tirofiban          | Class I       | 1             |
| 3  | 56/F     | SAH          | III | PComA     | Yes/Yes             | Small| ST         | Infarction     | No                   | Class II      | 2             |
| 4  | 55/M     | SAH          | IV  | AComA     | Yes/Yes             | Small| ST         | Infarction     | No                   | Class I       | 4             |
| 5  | 48/M     | SAH          | I   | MCA-bifur | Yes/Yes             | Small| ST         | Rupture        | Heparinisation was reversed +total occlusion +fasudil | Class I       | 1             |
| 6  | 49/F     | Incidental   | 0   | PComA     | Yes/Yes             | Small| ST         | Rupture        | Heparinisation was reversed +total occlusion | Class I       | 1             |

F, Female; M, Male; SAH, subarachnoid haemorrhage; H-H, Hunt-Hess Scale; MCA, middle cerebral artery; Bifur, Bifurcation; PComA, posterior communicating artery; AComA, the anterior communicating artery; ST, Solitaire.

doi:10.1371/journal.pone.0057253.t004
was up to 33% in the 54 saccular aneurysms (19/54), follow-up imaging revealed that 30 were cured (93%), 1 was improved (2%), and 3 were unchanged (5%). Moreover, post-treatment rebleeding was not encountered. These results support the view that stent implantation can lead to further occlusion of incompletely coiled aneurysms and prevent haemorrhage [15,17,19,26].

Stent implantation is regarded as a thrombogenic risk up until stent endothelialisation [27]. One concern is whether the increased quantity of embedded stents increases the risks of thromboembolic events. However, this series of 4 thromboembolic events all occurred in single-stent-assisted coiling, of which occurred in SAH patients. The univariate analysis showed that the predictor for thromboembolic events was not the quantity of embedded stents \( p < 0.05 \), but SAH \( p < 0.05 \), Table 2), which supports the idea that use of adjunctive devices in treating aneurysms does not increase the frequency of embolic or ischemic events [28]. The occurrence of these adverse events may be related to several causes, such as the relatively unfavourable anatomic access, the lack of experience in the early stage of treatment, the SAH-related hypercoagulable state [29], vasospasm, and the relatively short duration of antplatelet therapy prior to stent implantation. Additionally, we eliminated two thrombus events by the infusion of sole tirofiban (Case 2) and the combination of tirofiban and a second Solitaire stent implantation (Case 1). In contrast, post-procedural infarction events remained inevitable (Case 3–4), particularly in SAH patients, which required further investigation. In addition to SAH, the occlusion grade was also a predictor for overall adverse events \( p < 0.05 \), Table 2). The rate of to 96% (65/68) in tiny (n = 18) and small (n = 47) lesions might be responsible for this predictor.

In the early stage of treatment, 2 intraprocedural aneurysm ruptures were encountered, whose risk factors could not be identified \( p > 0.05 \), Table 2) due to the limited data. The pre-deployed stent enabled the rapid occlusion of ruptured lesions, preventing severe bleeding (Fig. 3A vs Fig. 3E). There were two independent cases that had mRS scores of 1 at discharge and at follow-ups (Case 5–6). These 2 small ruptured lesions were located on the posterior communicating artery (PComA) and the middle cerebral artery (MCA) bifurcation, which supports the viewpoint that the rate of intraoperative rupture is related to aneurysm size and location [30–31].

Another principal finding was that SAH was the only predictor for unfavourable outcomes (mRS, 2–6) by univariate analysis \( p < 0.05 \), Table 3). This suggests that SAH is involved in the outcomes of unruptured [10] or ruptured [32] vertebrobasilar artery dissections, but it appears to be discordant with the role of SAH in saccular aneurysm outcomes [33]. This may be explained by differing definitions of clinical outcomes in a study by Tahitinen et. al. where good clinical outcome was defined by a Glasgow Outcome Scales (GOS) score of 3, moderate outcome by a GOS score of 3 or 4, and poor outcome by a GOS score of 1 or 2 [33].

Conclusions
Although the complete obliteration of tiny and small wide-necked aneurysms without complications remains a technical challenge, stent implantation can lead to further occlusion of incompletely coiled aneurysms. The predictors for adverse events primarily involved SAH and the occlusion grade. SAH was the only predictor for unfavourable outcomes by univariate analysis.

Author Contributions
Revised the article: Y-WZ. YX BH P-FY J-ML. Collected the data: W-YZ. Conceived and designed the experiments: K-JZ Y-WZ J-ML. Analyzed the data: YX BH Q-HH W-YZ. Wrote the paper: K-JZ.

References
1. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Stracel M, et al. (2005) International Subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2145 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and distribution of aneurysms with detachable coils. Lancet 366: 809–817.
2. Molyneux A, Kerr R, Stratton I, Sandrock P, Clarke M, et al. (2002) International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: randomised trial. Lancet 360: 1267–1274.
3. Pierot L, Cognard C, Anxionnat R, Ricolfi F (2011) Remodeling technique for aneurysms and location [30–31].
23. Fiorella D, Woo HH, Albuquerque FC, Nelson PK (2008) Definitive reconstruction of circumferential, fusiform intracranial aneurysms with the pipeline embolization device. Neurosurgery 62: 1115–1120; discussion 1120–1111.

24. Huang QH, Wu YF, Xu Y, Hong B, Zhang L, et al. (2011) Vascular geometry change because of endovascular stent placement for anterior communicating artery aneurysms. AJNR Am J Neuroradiol 32: 1721–1723.

25. Meng H, Wang Z, Kim M, Ecker RD, Hopkins LN (2006) Saccular aneurysms on straight and curved vessels are subject to different hemodynamics: implications of intravascular stenting. AJNR Am J Neuroradiol 27: 1861–1865.

26. Maldonado II, Machi P, Costalat V, Mura T, Bonafe A (2011) Neuroform stent-assisted coiling of unruptured intracranial aneurysms: short- and midterm results from a single-center experience with 68 patients. AJNR Am J Neuroradiol 32: 131–136.

27. Lopes D, Sani S (2005) Histological postmortem study of an internal carotid artery aneurysm treated with the Neuroform stent. Neurosurgery 56: E416; discussion E416.

28. Brooks NP, Turk AS, Niemann DB, Aagaard-Kienitz B, Pölfer K, et al. (2008) Frequency of thromboembolic events associated with endovascular aneurysm treatment: retrospective case series. J Neurosurg 108: 1095–1100.

29. Larsen CC, Hansen-Schweitz J, Nielsen JD, Astrup J (2010) Blood coagulation and fibrinolysis after experimental subarachnoid hemorrhage. Acta Neurochir (Wien) 152: 1577–1581; discussion 1581.

30. Schuette AJ, Hui FK, Spiotta AM, Obuchowski NA, Gupta R, et al. (2011) Endovascular therapy of very small aneurysms of the anterior communicating artery: five-fold increased incidence of rupture. Neurosurgery 68: 731–737; discussion 737.

31. Pierot L, Cognard C, Anxionnat R, Ricolfi F (2010) Ruptured intracranial aneurysms: factors affecting the rate and outcome of endovascular treatment complications in a series of 782 patients (CLARITY study). Radiology 256: 914–923.

32. Lee JM, Kim TS, Joo SP, Yoon W, Choi HY (2010) Endovascular treatment of ruptured dissecting vertebral artery aneurysms: long-term follow-up results, benefits of early embolization, and predictors of outcome. Acta Neurochir (Wien) 152: 1455–1465.

33. Tahtinen OI, Vanninen RL, Manninen HI, Rautio R, Haapanen A, et al. (2009) Wide-necked intracranial aneurysms: treatment with stent-assisted coil embolization during acute (<72 hours) subarachnoid hemorrhage–experience in 61 consecutive patients. Radiology 253: 199–208.